Bionano Genomics- Warrants (21/08/2023) Profit Margin

The latest profit margin for BNGOW is -106.58% as of June 2026. That compares with -271.02% in the prior-year period — up 60.7% year over year. That is below the Healthcare sector average of 13.39%. Investors often review this figure alongside Bionano Genomics- Warrants (21/08/2023)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, BNGOW's profit margin moved from -271.02% to -106.58% — a 60.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bionano Genomics- Warrants (21/08/2023)'s valuation or profitability profile.

Against Healthcare companies, BNGOW currently prints -106.58% for profit margin, while the sector average sits near 13.39%. That is roughly 896.2% below the sector mean. Large gaps often invite a closer look at Bionano Genomics- Warrants (21/08/2023)'s growth, margins, and balance sheet.

Profit Margin shows how effectively Bionano Genomics- Warrants (21/08/2023) converts resources into returns. At -106.58%, BNGOW may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -271.02% in the prior-year period — up 60.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BNGOW's profit margin (-106.58%), review year-over-year change from -271.02%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.